Reportlinker Adds World Market for Diabetes Treatments

Oct 12, 2010, 07:17 ET from Reportlinker

NEW YORK, Oct. 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Market for Diabetes Treatments

http://www.reportlinker.com/p0311454/World-Market-for-Diabetes-Treatments.html

This Kalorama Information report , The World Market for Diabetes Treatments, provides market estimates and forecasts for the world market for diabetes treatments. The diabetes market is one of the fastest growing markets within the pharmaceutical sector, and is one of the few pharmaceutical sectors that are likely to continue to grow at double digit rates throughout the forecast period. Major contributing factors to growth are increasing obesity and an aging worldwide population. The total market for diabetes treatments is divided into two major segments:

  • Insulin Markets in US, Europe, Japan, ROW

  • Oral Hypoglycemics in US, Europe, Japan, ROW

For each of these market segments the report provides market share and regional breakout (US, Europe, Asia, ROW). The report also discusses treatment for diabetes complications and natural and herbal treatments.

The report's geographic scope is worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market. Trends covered in the report include:

  • New Products and the Development Pipeline (Afrezza,

Bydureon, Syncria, AVE0010, Balaglitazone, Metgluna

Otelixizumab and others)

  • Transplantation Research Efforts

  • A-Cell Transplantation Research

  • Potential New Drug for Type 2 Diabetes

  • Insulin Pills

  • Three-month Insulin Shot

  • Outsourcing of Diabetes Projects

  • Reclassification of Cause of Death

Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets.

A market summary includes market analysis by product and region and a competitive analysis of leading providers. Additionally, key company profiles are included, including profiles of the following:

  • Amylin Pharmaceuticals

  • AstraZeneca

  • GlaxoSmithKline

  • Eli Lilly & Co.

  • Merck

  • Metabolex, Inc.

  • Novo Nordisk A/S

  • Pfizer Inc.

  • Sanofi-Aventis Group

  • Takeda Pharmaceutical Company Limited

CHAPTER ONE: EXECUTIVE SUMMARY

Background

Scope and Methodology

Size and Growth of the Market

Key Issues and Trends Affecting Market

Leading Competitors

CHAPTER TWO: INTRODUCTION

Background

Therapeutic Practices

France

Germany

Italy

Japan

Spain

United Kingdom

United States

China

India

CHAPTER THREE: CURRENT THERAPEUTICS FOR DIABETES

Insulin

Regular Insulin

Long-Acting and Basal Insulin

Rapidly Acting Insulin

Combinations

Insulin Pumps

Insulin Pens

Inhaled Insulin

Other Treatments

Oral Hypoglycemics

Sulfonylureas Biguanides

a-Glucosidase Inhibitors

Thiazolidinediones

Meglitinides

D-Phenylalanine Derivatives

GLP1 Agonists

DPP-IV Inhibitor

Current Therapeutics for Diabetic Complications

Antihypertensive Therapy

ACE Inhibitors

a/a(Alpha/Beta)-Blockers

Calcium Channel Blockers

Diuretics

Angiotensin II Receptor Antagonists

Dyslipidemia Therapy

HMG-CoA Reductase Inhibitors--Statins

Bile Acid Sequestrants

Fibric Acid Derivatives

Niacin

Cholesterol Absorption Inhibitors

Atherosclerosis Therapy

Arrhythmia Therapy

Peripheral Vascular Disease Therapy

CHAPTER THREE: TOTAL MARKET REVENUES, FORECAST AND COMPETITIVE ANALYSIS

Total Worldwide Diabetes Market Analysis by Geographic Segment

Total Worldwide Diabetes Market Competitive Analysis

Total Worldwide Diabetes Market by Segment

Insulin

Oral Hypoglycemics

CHAPTER FOUR: KEY ISSUES, TRENDS AND DEVELOPMENTS

New Products and the Development Pipeline

Afrezza

Bydureon

Syncria

AVE0010 Once Daily and Twice Daily

Balaglitazone

Dapagliflozin and Dapagliflozin/Meformin Fixed Dose Combination

Degludec and Degludec Plus

Daimyd Vaccine

Dutogliptin

Glinsuma, Glufast, Metgluna

MK 0431C

Ondero

Oral-lyn

Otelixizumab

Taspoglutide

Transplantation Research Efforts

A-Cell Transplantation Research

Potential New Drug for Type 2 Diabetes

Insulin Pills

Three-month Insulin Shot

Outsourcing of Diabetes Projects

Reclassification of Cause of Death

CHAPTER FIVE: NUTRITIONAL SUPPLEMENT AND HERBAL APPROACHES TO THE TREATMENT OF DIABETES

Background

Nutritional Supplements

Ascorbic Acid (Vitamin C)

Biotin

Chromium

Copper

Magnesium

Niacin and Niacinamide

Potassium

Selenium

Thiamine

Vanadium

Vitamin B6 (Pyridoxine)

Vitamin B12

Vitamin E

Zinc

Nutritional Treatment of Diabetic Neuropathy

Herbal Treatment of Diabetes

Aloe (Various)

Arctium lappa (Burdock Root)

Allium cepa (Onion)

Grifola frondosa (Maitake Mushroom)

Mulberry

Panax ginseng (Korean ginseng)

Ayurvedic Medicine and Herbs

Gymnema sylvestre (Asclepias germinata)

Momordica charantia (Bitter Gourd)

Trigonella foenum graecum (Fenugreek)

Other Herbs with Significant Anti-Diabetic Effects

Traditional Chinese Medicine

CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS

First Conclusion

Implications:

Second Conclusion

Implications:

Third Conclusion

Implications:

Fourth Conclusion

Implications:

Fifth Conclusion

Implications:

Sixth Conclusion

Implications:

Seventh Conclusion

Implications:

Eighth Conclusion

Implications:

Ninth Conclusion

Implications:

Tenth Conclusion

Implications:

Eleventh Conclusion

Implications:

Twelfth Conclusion

Implications:

Thirteenth Conclusion

Implications:

Fourteenth Conclusion

Implications:

Fifteenth Conclusion

Implications:

CHAPTER SEVEN: LEADING MANUFACTURERS

Overview

Amylin Pharmaceuticals

AstraZeneca

GlaxoSmithKline

Eli Lilly & Co.

Merck

Metabolex, Inc.

Novo Nordisk A/S

Pfizer Inc.

Sanofi-Aventis Group

Takeda Pharmaceutical Company Limited

APPENDIX A: GLOSSARY

APPENDIX B: COMPANY DIRECTORY

To order this report:

Therapy Industry: World Market for Diabetes Treatments

Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com